These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5055042)

  • 41. Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis.
    Kahl LE; Medsger TA; Klein I
    J Rheumatol; 1985 Oct; 12(5):990-1. PubMed ID: 4087275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Treatment of systemic scleroderma with D-penicillamine. Results in 14 patients treated for more than a year].
    Kahn MF; Bourgeois P; Brion N; Elleuch M
    Rev Rhum Mal Osteoartic; 1986 Jan; 53(1):35-8. PubMed ID: 3704510
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toxic hepatitis after therapeutic doses of benorylate and D-penicillamine.
    Sacher M; Thaler H
    Lancet; 1977 Feb; 1(8009):481-2. PubMed ID: 65582
    [No Abstract]   [Full Text] [Related]  

  • 44. [Clinical use of d-penicillamine, complications and possibilities of their prevention].
    Krel' AA; Ivanova TS
    Ter Arkh; 1977; 49(10):138-44. PubMed ID: 145661
    [No Abstract]   [Full Text] [Related]  

  • 45. D-penicillamine in progressive scleroderma.
    Lorenzen I; Uitto J; Ohlenschlaeger K
    Scand J Rheumatol; 1972; 1(3):121-4. PubMed ID: 4667928
    [No Abstract]   [Full Text] [Related]  

  • 46. Nephrotic syndrome induced by penicillamine.
    Stein J; Smythe HA
    Can Med Assoc J; 1968 Mar; 98(10):505-7. PubMed ID: 5645186
    [No Abstract]   [Full Text] [Related]  

  • 47. [Analysis of the distribution of class I HLA-antigens in patients with systemic scleroderma with regard to features of the clinical course of the disease and therapy with D-penicillamine].
    Pevnitskiĭ LA; Guseva NG; Sibiriakova LG; Oskilko TG
    Genetika; 1989 Jun; 25(6):1101-7. PubMed ID: 2806895
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of penicillin and D-penicillamine on beta-galactosidase activity in patients with progressive scleroderma].
    Schulze E; Herrmann K; Haustein UF; Krusche U; Rothenburger I
    Dermatol Monatsschr; 1988; 174(11):661-6. PubMed ID: 3145222
    [No Abstract]   [Full Text] [Related]  

  • 49. Hepatotoxicity of papaverine.
    Kiaer HW; Olsen S; Ronnov-Jessen V
    Arch Pathol; 1974 Nov; 98(5):292-6. PubMed ID: 4413667
    [No Abstract]   [Full Text] [Related]  

  • 50. Progressive systemic sclerosis and penicillamine.
    Rodnan GP
    J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Effects and adverse effects of D-penicillamine].
    Perings E; Junge U
    Med Klin; 1975 Aug; 70(31):1265-74. PubMed ID: 1107780
    [No Abstract]   [Full Text] [Related]  

  • 52. The treatment of cystinuria with N-acetyl-D-penicillamine, a comparison with the results of D-penicillamine treatment.
    Stephens AD; Watts RW
    Q J Med; 1971 Jul; 40(159):355-70. PubMed ID: 5564534
    [No Abstract]   [Full Text] [Related]  

  • 53. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.
    Shapiro LS; Prince RK; Buckingham RB; Rodnan GP
    J Rheumatol; 1983 Apr; 10(2):316-8. PubMed ID: 6864687
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prevention and dissolution of cystine stones by D-penicillinamine].
    Oliver L; Liberman AU; De Vries A
    Harefuah; 1973 Jan; 84(1):11-3. PubMed ID: 4692793
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antibodies against D-penicillamine in primary biliary cirrhosis].
    Storch W
    Immun Infekt; 1990 Feb; 18(1):22-3. PubMed ID: 2179124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Microcirculatory disorders in systemic scleroderma treated with d-penicillamine].
    Nasonova VA; Alekberova ZS; Mach ES; Balabanova RM
    Klin Med (Mosk); 1981 Nov; 59(11):57-61. PubMed ID: 7321499
    [No Abstract]   [Full Text] [Related]  

  • 57. Penicillamine therapy in systemic sclerosis.
    Jayson MI; Lovell C; Black CM; Wilson RS
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):82-8. PubMed ID: 122683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Marked proteinuria in the course of penicillamine treatment of progressive systemic sclerosis].
    Filipecki S; Dabrowska B; Szczepański A; Glyda J
    Pol Tyg Lek; 1971 Nov; 26(46):1780-1. PubMed ID: 5131995
    [No Abstract]   [Full Text] [Related]  

  • 59. [Treatment of interstitial pulmonary fibrosis with D-penicillamine in progressive scleroderma: a long-term study (author's transl)].
    Bröll H; Tausch G; Eberl R
    Wien Klin Wochenschr; 1976 Apr; 88(9):292-5. PubMed ID: 973388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Two years of penicillamine for progressive systemic sclerosis: a case report.
    Thomson J; Milne JA
    Postgrad Med J; 1974 Aug; 50 Suppl 2():36-8. PubMed ID: 4467175
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.